{"id":77727,"date":"2026-09-01T12:00:08","date_gmt":"2026-09-01T04:00:08","guid":{"rendered":"https:\/\/flcube.com\/?p=77727"},"modified":"2026-09-01T12:00:09","modified_gmt":"2026-09-01T04:00:09","slug":"baheal-pharma-invests-rmb-40-million-in-jikun-medical-to-accelerate-jk1033-idiopathic-pulmonary-fibrosis-drug","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77727","title":{"rendered":"Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China-based <strong>Baheal Pharmaceutical Group Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/301015:SHE\">SHE: 301015<\/a>)<\/strong> announced plans to invest <strong>RMB 40 million<\/strong> in <strong>Tianjin Jikun Medical Technology Co., Ltd.<\/strong> (\u201c<strong>Jikun Medical<\/strong>\u201d), deepening its strategic footprint in the organ fibrosis field. Upon completion, <strong>Baheal Pharma<\/strong> will hold a <strong>25.4399% equity stake<\/strong> in <strong>Jikun Medical<\/strong>, reinforcing its commitment to fibrosis-focused therapeutics including the lead candidate <strong>JK1033<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-overview-amp-strategic-terms\" class=\"wp-block-heading\">Deal Overview &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Investor<\/td><td><strong>Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015)<\/strong><\/td><\/tr><tr><td>Target<\/td><td><strong>Tianjin Jikun Medical Technology Co., Ltd.<\/strong><\/td><\/tr><tr><td>Investment Size<\/td><td><strong>RMB 40 million<\/strong> (follow-on investment)<\/td><\/tr><tr><td>Post-Deal Equity Stake<\/td><td><strong>25.4399%<\/strong><\/td><\/tr><tr><td>Announcement Date<\/td><td><strong>29 Aug 2026<\/strong><\/td><\/tr><tr><td>Use of Proceeds<\/td><td>R&amp;D of <strong>JK1033<\/strong> (idiopathic pulmonary fibrosis), <strong>ADC<\/strong> candidates, other pipelines, and general operations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-pipeline-jk1033-and-adc-candidates\" class=\"wp-block-heading\">Drug Profile &amp; Pipeline \u2013 JK1033 and ADC Candidates<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead Molecule:<\/strong> <strong>JK1033<\/strong>, an investigational drug targeting <strong>idiopathic pulmonary fibrosis (IPF)<\/strong><\/li>\n\n\n\n<li><strong>Indication Focus:<\/strong> IPF \u2014 a progressive, life-threatening fibrotic lung disease with high unmet medical need<\/li>\n\n\n\n<li><strong>Platform Extension:<\/strong> Proceeds also fund <strong>antibody-drug conjugate (ADC)<\/strong> candidates, broadening <strong>Jikun Medical<\/strong>\u2019s pipeline beyond fibrosis<\/li>\n\n\n\n<li><strong>Strategic Rights:<\/strong> Under the 2025 cooperation agreement, <strong>Baheal Pharma<\/strong> secured priority purchase rights for certain <strong>Jikun Medical<\/strong> pharmaceutical products, plus priority negotiation rights for contract manufacturing and global commercialization<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-rationale\" class=\"wp-block-heading\">Commercial Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Follow-on Commitment:<\/strong> The transaction builds on <strong>Baheal Pharma<\/strong>\u2019s initial 2025 investment in <strong>Jikun Medical<\/strong> and an existing strategic cooperation agreement, signaling continued conviction in the partnership<\/li>\n\n\n\n<li><strong>Fibrosis Expansion:<\/strong> The additional capital strengthens <strong>Baheal Pharma<\/strong>\u2019s strategic presence across the organ fibrosis landscape, a therapeutic area with limited treatment options and growing demand<\/li>\n\n\n\n<li><strong>Vertical Integration:<\/strong> Priority purchase and commercialization rights position <strong>Baheal Pharma<\/strong> to capture downstream value from <strong>JK1033<\/strong> and future pipeline assets<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> Funding directed at <strong>ADC<\/strong> candidates adds a second growth vector alongside the fibrosis franchise<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The investment consolidates <strong>Baheal Pharma<\/strong>\u2019s role as a key strategic backer of <strong>Jikun Medical<\/strong>, with a meaningful 25.4399% minority stake<\/li>\n\n\n\n<li>Progress of <strong>JK1033<\/strong> will be the near-term catalyst to watch, given IPF\u2019s significant unmet need in China and globally<\/li>\n\n\n\n<li>The combined fibrosis + ADC pipeline broadens optionality for both companies and may support future licensing or co-development deals<\/li>\n\n\n\n<li>Deeper capital and commercial ties are expected to accelerate clinical advancement of <strong>Jikun Medical<\/strong>\u2019s lead programs<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward-looking statements regarding investment plans, pipeline development, and strategic cooperation that involve risks and uncertainties. Actual results may differ materially. Nothing herein constitutes investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/\u767e\u6d0b\u533b\u836f\uff1a\u5173\u4e8e\u5bf9\u5916\u6295\u8d44\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u767e\u6d0b\u533b\u836f\uff1a\u5173\u4e8e\u5bf9\u5916\u6295\u8d44\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-2351176d-3b77-4d05-b0d7-cceda1f5073a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/\u767e\u6d0b\u533b\u836f\uff1a\u5173\u4e8e\u5bf9\u5916\u6295\u8d44\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\">\u767e\u6d0b\u533b\u836f\uff1a\u5173\u4e8e\u5bf9\u5916\u6295\u8d44\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/\u767e\u6d0b\u533b\u836f\uff1a\u5173\u4e8e\u5bf9\u5916\u6295\u8d44\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2351176d-3b77-4d05-b0d7-cceda1f5073a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[288,4350,2011],"class_list":["post-77727","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-baheal-pharmaceutical","tag-jikun-pharmaceutical-technology","tag-she-301015"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million in Tianjin Jikun Medical Technology Co., Ltd. (\u201cJikun Medical\u201d), deepening its strategic footprint in the organ fibrosis field. Upon completion, Baheal Pharma will hold a 25.4399% equity stake in Jikun Medical, reinforcing its commitment to fibrosis-focused therapeutics including the lead candidate JK1033.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77727\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug\" \/>\n<meta property=\"og:description\" content=\"China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million in Tianjin Jikun Medical Technology Co., Ltd. (\u201cJikun Medical\u201d), deepening its strategic footprint in the organ fibrosis field. Upon completion, Baheal Pharma will hold a 25.4399% equity stake in Jikun Medical, reinforcing its commitment to fibrosis-focused therapeutics including the lead candidate JK1033.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77727\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T04:00:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T04:00:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77727#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77727\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug\",\"datePublished\":\"2026-09-01T04:00:08+00:00\",\"dateModified\":\"2026-09-01T04:00:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77727\"},\"wordCount\":402,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Baheal Pharmaceutical\",\"Jikun Pharmaceutical Technology\",\"SHE: 301015\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77727#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77727\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77727\",\"name\":\"Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-01T04:00:08+00:00\",\"dateModified\":\"2026-09-01T04:00:09+00:00\",\"description\":\"China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million in Tianjin Jikun Medical Technology Co., Ltd. (\u201cJikun Medical\u201d), deepening its strategic footprint in the organ fibrosis field. Upon completion, Baheal Pharma will hold a 25.4399% equity stake in Jikun Medical, reinforcing its commitment to fibrosis-focused therapeutics including the lead candidate JK1033.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77727#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77727\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77727#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million in Tianjin Jikun Medical Technology Co., Ltd. (\u201cJikun Medical\u201d), deepening its strategic footprint in the organ fibrosis field. Upon completion, Baheal Pharma will hold a 25.4399% equity stake in Jikun Medical, reinforcing its commitment to fibrosis-focused therapeutics including the lead candidate JK1033.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77727","og_locale":"en_US","og_type":"article","og_title":"Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug","og_description":"China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million in Tianjin Jikun Medical Technology Co., Ltd. (\u201cJikun Medical\u201d), deepening its strategic footprint in the organ fibrosis field. Upon completion, Baheal Pharma will hold a 25.4399% equity stake in Jikun Medical, reinforcing its commitment to fibrosis-focused therapeutics including the lead candidate JK1033.","og_url":"https:\/\/flcube.com\/?p=77727","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-01T04:00:08+00:00","article_modified_time":"2026-09-01T04:00:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77727#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77727"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug","datePublished":"2026-09-01T04:00:08+00:00","dateModified":"2026-09-01T04:00:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77727"},"wordCount":402,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Baheal Pharmaceutical","Jikun Pharmaceutical Technology","SHE: 301015"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77727#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77727","url":"https:\/\/flcube.com\/?p=77727","name":"Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-01T04:00:08+00:00","dateModified":"2026-09-01T04:00:09+00:00","description":"China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million in Tianjin Jikun Medical Technology Co., Ltd. (\u201cJikun Medical\u201d), deepening its strategic footprint in the organ fibrosis field. Upon completion, Baheal Pharma will hold a 25.4399% equity stake in Jikun Medical, reinforcing its commitment to fibrosis-focused therapeutics including the lead candidate JK1033.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77727#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77727"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77727#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77727"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77727\/revisions"}],"predecessor-version":[{"id":77730,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77727\/revisions\/77730"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}